Pulse Biosciences is a bioelectric medicine company. The CellFX® System (CellFX) is the commercial product to harness the distinctive advantages of Co.'s proprietary Nano-Pulse Stimulation (NPS) technology, such as the ability to non-thermally clear cells while sparing non-cellular tissue, to treat a variety of conditions for which an optimal solution remains unfulfilled. The CellFX System is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. Co. has also designed an integrated cloud software infrastructure called CellFX CloudConnect. CellFX CloudConnect also facilitates direct connectivity to the CellFX System. The PLSE stock yearly return is shown above.
The yearly return on the PLSE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PLSE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|